CCL2 and diabetes mellitus: Furthermore, DPP4i can reduce pro‐inflammatory cytokines, such as MCP‐1,71 which is associated with atherosclerotic plaques and visceral fat, which both contribute to immune‐inflammatory disease, closely associated with diabetes.